• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Neurofibromatoses Type I (Von Recklinghausen's Disease) - Pipeline Review, H2 2012 Product Image

Neurofibromatoses Type I (Von Recklinghausen's Disease) - Pipeline Review, H2 2012

  • ID: 2366302
  • December 2012
  • 35 pages
  • Global Markets Direct

Neurofibromatoses Type I (Von Recklinghausen’s Disease) – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Neurofibromatoses Type I (Von Recklinghausen’s Disease), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Neurofibromatoses Type I (Von Recklinghausen’s Disease). Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for READ MORE >

2
List of Tables 3
List of Figures 3
Introduction 4
REPORT COVERAGE 4
Neurofibromatoses Type I (Von Recklinghausen’s Disease) Overview 5
Therapeutics Development 6
An Overview of Pipeline Products for Neurofibromatoses Type I (Von Recklinghausen’s Disease) 6
Neurofibromatoses Type I (Von Recklinghausen’s Disease) Therapeutics under Development by Companies 8
Neurofibromatoses Type I (Von Recklinghausen’s Disease) Therapeutics under Investigation by Universities/Institutes 9
Mid Clinical Stage Products 10
Comparative Analysis 10
Early Clinical Stage Products 11
Comparative Analysis 11
Neurofibromatoses Type I (Von Recklinghausen’s Disease) Therapeutics – Products under Development by Companies 12
Neurofibromatoses Type I (Von Recklinghausen’s Disease) Therapeutics – Products under Investigation by Universities/Institutes 13
Companies Involved in Neurofibromatoses Type I (Von Recklinghausen’s Disease) Therapeutics Development 14
Plexxikon Inc. 14
Light Sciences Oncology, Inc. 15
Neurofibromatoses Type I (Von Recklinghausen’s Disease) – Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Route of Administration 17
Assessment by Molecule Type 19
Drug Profiles 21
talaporfin sodium - Drug Profile 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
sirolimus - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
sorafenib tosylate - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
cediranib maleate - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
PLX-3397 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Neurofibromatoses Type I (Von Recklinghausen’s Disease) Therapeutics – Drug Profile Updates 31
Neurofibromatoses Type I (Von Recklinghausen’s Disease) Therapeutics - Dormant Products 33
Appendix 34
Methodology 34
Coverage 34
Secondary Research 34
Primary Research 34
Expert Panel Validation 34
Contact Us 35
Disclaimer 35

List of Tables
Number of Products Under Development for Neurofibromatoses Type I (Von Recklinghausen’s Disease), H2 2012 6
Products under Development for Neurofibromatoses Type I (Von Recklinghausen’s Disease) – Comparative Analysis, H2 2012 7
Number of Products under Development by Companies, H2 2012 8
Number of Products under Investigation by Universities/Institutes, H2 2012 9
Comparative Analysis by Mid Clinical Stage Development, H2 2012 10
Comparative Analysis by Early Clinical Stage Development, H2 2012 11
Products under Development by Companies, H2 2012 12
Products under Investigation by Universities/Institutes, H2 2012 13
Plexxikon Inc., H2 2012 14
Light Sciences Oncology, Inc., H2 2012 15
Assessment by Monotherapy Products, H2 2012 16
Assessment by Stage and Route of Administration, H2 2012 18
Assessment by Stage and Molecule Type, H2 2012 20
Neurofibromatoses Type I (Von Recklinghausen’s Disease) Therapeutics – Drug Profile Updates 31
Neurofibromatoses Type I (Von Recklinghausen’s Disease) Therapeutics – Dormant Products 33

List of Figures
Number of Products under Development for Neurofibromatoses Type I (Von Recklinghausen’s Disease), H2 2012 6
Products under Development for Neurofibromatoses Type I (Von Recklinghausen’s Disease) – Comparative Analysis, H2 2012 7
Products under Development by Companies, H2 2012 8
Products under Investigation by Universities/Institutes, H2 2012 9
Mid Clinical Stage Products, H2 2012 10
Early Clinical Stage Products, H2 2012 11
Assessment by Monotherapy Products, H2 2012 16
Assessment by Route of Administration, H2 2012 17
Assessment by Stage and Route of Administration, H2 2012 18
Assessment by Molecule Type, H2 2012 19
Assessment by Stage and Molecule Type, H2 2012 20

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos